TOT Biopharm opens new production facility in China
TOT Biopharm has held an inauguration ceremony for its new factory complex in Suzhou, China.
TOT Biopharm Company Ltd has opened a new factory in eastern China.
Stage one of its new high-tech production factory complex in the Suzhou Industrial Park has now been completed, with an inauguration ceremony being held in November.
The $100 million factory will specialise in the research and development, production and marketing of anti-cancer drugs and represents a milestone in the cooperation between the biopharmaceutical sectors in mainland China and Taiwan.
As such, the inauguration ceremony was attended by business leaders from both regions, including Wang Shaobang, deputy director of the Taiwan Affairs Office of Jiangsu Province; Yang Zhiping, director of Suzhou Industrial Park; and Gao Konglian, deputy chairman of Straits Exchange Foundation.
The first stage of the new factory complex provides manufacturing facilities for an oral anti-cancer drug, alongside production facilities for cytotoxics, non-cytotoxics and an injected anti-cancer drug, and a GMP bio pilot plant.
TOT Biopharm will now commence construction on the second stage of its new factory complex, providing additional production capacity.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.